Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms

الملخص EN

Background.

Myeloproliferative neoplasms are a heterogeneous group of disorders resulting from the abnormal proliferation of one or more terminal myeloid cells—established complications include thrombosis and haemorrhagic events; however, there is limited evidence to suggest an association with arterial hypertension.

Herein, we report two independent cases of severe hypertension in JAK2 mutation-positive myeloproliferative neoplasms.

Case Presentations.

Case 1: a 39-year-old male was referred to our specialist hypertension unit with high blood pressure (BP) (200/120 mmHg), erythromelalgia, and headaches.

We recorded elevated serum creatinine levels (146 μM) and panmyelosis.

Bone marrow biopsy confirmed JAK2-mutation-positive polycythaemia vera.

Renal imaging revealed renal artery stenosis.

Aspirin, long-acting nifedipine, interferon-alpha 2A, and renal artery angioplasty were employed in management.

BP reached below target levels to an average of 119/88 mmHg.

Renal parameters normalised gradually alongside BP.

Case 2: a 45-year-old male presented with high BP (208/131 mmHg), acrocyanosis, (vasculitic) skin rashes, and nonhealing ulcers.

Fundoscopy showed optic disc blurring in the left eye and full blood count revealed thrombocytosis.

Bone marrow biopsy confirmed JAK2-mutation-positive essential thrombocytosis.

No renal artery stenosis was found.

Cardiac output was measured at 5 L/min using an inert gas rebreathing method, providing an estimated peripheral vascular resistance of 1840 dynes/s/cm5.

BP was well-controlled (reaching 130/70 mmHg) with CCBs.

Conclusions.

These presentations highlight the utility of full blood count analysis in patients with severe hypertension.

Hyperviscosity and constitutive JAK-STAT activation are amongst the proposed pathophysiology linking myeloproliferative neoplasms and hypertension.

Further experimental and clinical research is necessary to identify and understand possible interactions between BP and myeloproliferative neoplasms.